Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer
An observational study in patients with advanced ER+, HER2 negative breast cancer, who are treated with everolimus and exemestane in combination. The objective of the study is to assess the safety pattern of everolimus in a real world setting.
Breast Cancer
DRUG: Everolimus and exemestane
Adverse Events, Up to 2.5 years
Progression free survival, Up to 2.5 years|Overall response rate, Up to 2.5 years|Clinical benefit rate, Up to 2.5 years|Overall survival, Up to 2.5 years|Time on treatment with everolimus, Up to 2.5 years|Reason for stopping treatment with everolimus, Up to 2.5 years
An observational study in patients with advanced ER+, HER2 negative breast cancer, who are treated with everolimus and exemestane in combination. The objective of the study is to assess the safety pattern of everolimus in a real world setting.